Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. (PRTK): 5 pipeline candidates · ~104 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
103.9 months
D/E -1.72 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for Paratek Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$42.8M
Quarterly Burn
$1.8M
Runway
103.9 mo
Revenue
$40.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| nuzyra | Phase 3 |
| omadacycline | Phase 1 |
| omadacycline injection [nuzyra] | Phase 1 |
| seysara | Approved |
| xhance | Approved |
Frequently asked questions
How many drug candidates are in Paratek Pharmaceuticals, Inc.'s pipeline?
Paratek Pharmaceuticals, Inc. (PRTK) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Paratek Pharmaceuticals, Inc.'s lead drug candidate?
Paratek Pharmaceuticals, Inc.'s most advanced tracked candidate is nuzyra (Phase 3) for Bacterial Infections.
What is Paratek Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Paratek Pharmaceuticals, Inc. has approximately 103.9 months of cash runway.
Who is the CEO of Paratek Pharmaceuticals, Inc.?
Contents Notice is the chief executive officer of Paratek Pharmaceuticals, Inc. (PRTK).
Get the full picture on Paratek Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.